lapatinib has been researched along with ici 118551 in 1 studies
Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (ici 118551) | Trials (ici 118551) | Recent Studies (post-2010) (ici 118551) |
---|---|---|---|---|---|
1,919 | 305 | 1,442 | 19 | 0 | 10 |
Protein | Taxonomy | lapatinib (IC50) | ici 118551 (IC50) |
---|---|---|---|
Beta-2 adrenergic receptor | Homo sapiens (human) | 0.0017 | |
Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.0005 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Dahal, A; Gu, X; Jois, S; Mattheolabakis, G; Singh, SS; Withers, S | 1 |
1 other study(ies) available for lapatinib and ici 118551
Article | Year |
---|---|
A grafted peptidomimetic for EGFR heterodimerization inhibition: Implications in NSCLC models.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dimerization; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Peptides; Peptidomimetics; Phosphorylation; Protein Interaction Domains and Motifs; Protein Kinase Inhibitors; Transplantation, Heterologous | 2021 |